Moleculin Biotech, Inc. MBRX

Hardly big pharma manipulated on this level of trading volume. I own more than the total trading volume most days. Ok with me if someone wants to play for lunch money on a daily basis if and until pivotal data occurs. I think this keeps mgmt focused on recruiting and managing trials and clinical sites and less on screwing the stock holders as they tried with the recent rs bs and absurd try for increasing authorized shares etc. If it’s a go, I want my best leverage for my investment. If not, I’ll have a good write off next year.

Tomorrow is the 8th anniversary of MBRX’s existence. Will it come and go without marking the occasion with a reason to celebrate or any mention at all?

Friday is MBRX’s 8th anniversary!

Should be interesting in mid-August one way or another. Mgmt time to fish or cut bait

Got a friend with STS lung C who checks all the boxes for eligibility in the trial and is considering applying. I hope for his recovery most of all but know there is no hope with current therapies. If he does I will have a first hand trial of 1 to analyze how good this is stuff really is.

Capital stock is still 71m shares after failed rs. Had it succeeded, capital stock would have jumped to 96m and they were trying to double that to 200m with the increase in authorized sh proposal. Now mgmt has a short leash to manage this over the fin in sh line.

Great news on defeat of r/s. Based on the data in q2, we should be seeing news of pulling the plug on p2 and a kickoff of a pivotal trial during q3 update or we will be having a different discussion on management competence in mid August. IMHO

By my calculations they needed about 500,000 yes votes two weeks ago. My shares represented 5% of that and I voted no to this insane power grab. They were badgering me every other day but no more.

Only thing clear to me in key proxy vote items is the company trying to reduce the power of existing shareholders back to unnecessary company discretion in ways that almost emulate taking it private. To what purpose, I don’t know but there is a slight of hand strategy in play here. First, they got rid of a major loc, why? - this is not a subtle hint! Second, the insiders are relatively quiet on share purchase to prop up the sp. to match their public enthusiasm. And Third, the frequent data dumps, while not necessarily negative, does tacitly suggest a long, protracted approval pivotal cycle which dampens investor interest and enthusiasm even more than saying nothing at all-why do that? It’s like a thank you for your contribution but we don’t need you anymore strategy.

A 1:8 rs gives management about 36% more unissued shares, about 25 million more . Why, because after the split, there’s no adjustment to number of authorized shares. It’s in their proxy detail . This is slight of hand while you’re watching their attempt to increase authorized shares by 100M (failed), they potentially get the 25M if rs is approved..